RIFAXIMIN - Generic Drug Details

What are the generic drug sources for rifaximin and what is the scope of patent protection?

Rifaximin is the generic ingredient in one branded drug marketed by Salix Pharms and is included in one NDA. There are twenty patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Rifaximin has one hundred and twenty-three patent family members in thirty-one countries.

There are fourteen drug master file entries for rifaximin. Three suppliers are listed for this compound. There are six tentative approvals for this compound.

Summary for RIFAXIMIN

International Patents:	123
US Patents:	20
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	14
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	198
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RIFAXIMIN
What excipients (inactive ingredients) are in RIFAXIMIN?	RIFAXIMIN excipients list
DailyMed Link:	RIFAXIMIN at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RIFAXIMIN

Dosage:

TABLET;ORAL

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RIFAXIMIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Universitt Luzern	PHASE4
Fundacin GECP	PHASE2
Rising Tide Foundation	PHASE2

See all RIFAXIMIN clinical trials

Generic filers with tentative approvals for RIFAXIMIN

Applicant	Application No.	Strength	Dosage Form
		550MG	TABLET;ORAL
		550MG	TABLET;ORAL
		200MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for RIFAXIMIN

Drug Class

Rifamycin Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for RIFAXIMIN

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

D06AX	Other antibiotics for topical use
D06A	ANTIBIOTICS FOR TOPICAL USE
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D	Dermatologicals

Paragraph IV (Patent) Challenges for RIFAXIMIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XIFAXAN	Tablets	rifaximin	200 mg	021361	1	2019-01-28
XIFAXAN	Tablets	rifaximin	550 mg	021361	1	2015-12-18

US Patents and Regulatory Information for RIFAXIMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes			Y
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004		RX	Yes	Yes
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes

Expired US Patents for RIFAXIMIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-001	May 25, 2004

International Patents for RIFAXIMIN

Country	Patent Number	Title	Estimated Expiration
South Korea	20120030542	MODULATION OF SYSTEMIC EXPOSURE TO RIFAXIMIN
China	102548408	Methods of treating hepatic encephalopathy
South Korea	20170036116	간성 뇌병증의 치료방법 (Methods of treating hepatic encephalopathy)
Canada	2773982
Portugal	3628319

Market Dynamics and Financial Trajectory for Rifaximin

Last updated: March 5, 2026

What Is the Current Market Size for Rifaximin?

The global Rifaximin market was valued at approximately $830 million in 2022. The compound annual growth rate (CAGR) is projected at 6.2% from 2023 to 2030, reaching an estimated $1.4 billion in 2030. The growth is driven by expanding indications, rising prevalence of digestive disorders, and increased adoption in infectious disease treatments.

Year	Market Valuation (USD million)	CAGR (%)
2022	830	–
2030	1,400	6.2

What Are the Key Drivers of Market Expansion?

Increasing Incidence of Digestive Disorders

Rifaximin is primarily used to treat traveler’s diarrhea, hepatic encephalopathy, and irritable bowel syndrome with diarrhea (IBS-D). Rising cases of these conditions lift demand.

Growing Use in Hepatology

Hepatic encephalopathy, linked to liver cirrhosis, affects an estimated 50,000 to 100,000 patients annually in the U.S. alone. Rifaximin is approved for reducing recurrence.

Expanding Approved Indications

In 2019, the FDA approved rifaximin for IBS-D. This label expansion adds to its existing uses, broadening market potential.

Increasing Awareness and Healthcare Access

Rising healthcare infrastructure and awareness in emerging markets, especially China and India, contribute to sales growth.

What Are the Challenges and Constraints?

Patent Expiry and Generic Competition

Novo Nordisk’s Xifaxan (marketed as Xifaxan 550 mg, 550 mg dosage) holds patents until 2024 in the U.S. and expires earlier in some markets. Generic versions are entering the market, pressuring pricing and margins.

Pricing Pressures and Reimbursement

In several markets, insurers and health systems restrict reimbursements, reducing profit margins.

Limited Market Penetration in Developing Regions

Despite rising prevalence, limited healthcare infrastructure hampers commercialization in some emerging markets.

Regulatory and Clinical Barriers

Additional clinical trials are often required to approve new indications, delaying market expansion.

What Are the Historical Financial Trends?

Xifaxan (Novo Nordisk) remained the dominant commercial product, generating sales of $630 million in 2022, declining modestly from a peak of $770 million in 2018. Revenue stability is threatened by the impending patent expiry.

Generic manufacturers have launched lower-priced versions in markets such as India and parts of Europe, creating price competition early in 2023.

What Are the Major Strategic Moves?

Patent Litigation and Extended Data Exclusivity

Novo Nordisk vigorously defends its patent estate until 2024. Patent extensions and litigation aims to delay generic entry.

Portfolio Diversification

Research is ongoing into other formulations and delivery systems, including use for small intestinal bacterial overgrowth (SIBO).

Licensing and Partnerships

Companies such as Salix Pharmaceuticals and others explore licensing deals to expand indications or access new markets.

Market Entry Strategies

Companies leverage local partnerships in emerging markets to navigate regulatory pathways and secure early market share.

How is the Competitive Landscape Shaping?

Company	Product	Market Share (2022)	Key Markets	Notable Initiatives
Xifaxan (Novo Nordisk)	Rifaximin oral	80%	U.S., Europe, Asia	Patent defense, indication expansion
Sandoz (Novartis)	Generic Rifaximin	15%	India, Europe	Price competition, market penetration
Others	Various generics	5%	Emerging markets	Focus on cost-sensitive segments

What Are the Regulatory and Policy Outlooks?

• Patent expirations in the U.S. are scheduled for 2024, enabling generics to enter the market.
• FDA reviews are ongoing for new indications, potentially extending market relevance.
• Pricing regulations in Europe and the U.S. may tighten, constraining revenue growth.

How Will the Financial Trajectory Evolve?

Revenue is forecasted to decline modestly post-2024 due to patent erosion, unless new indications or formulations are approved. Market share gains from generics may compress margins, requiring companies to innovate to sustain profitability.

What Are the Key Takeaways?

• The Rifaximin market is sizable with steady growth driven by expanding indications and increased awareness.
• Patent expiry in 2024 creates significant generic competition, risking revenue decline.
• Strategic efforts focus on litigation, indication expansion, and entering new markets.
• Price pressures and reimbursement policies pose ongoing challenges.
• Future growth hinges on new clinical data, regulatory approvals, and market penetration strategies.

FAQs

1. When will generic Rifaximin products enter the U.S. market?
Generic versions are expected post-2024 once patents expire, with some launches already occurring in India and Europe.

2. What new indications are under clinical development?
Research includes SIBO, prophylaxis for hepatic encephalopathy, and additional gastrointestinal disorders.

3. How does patent litigation influence market strategy?
Patent litigation can prolong exclusivity, delaying generics, and maintaining higher pricing for branded products.

4. Are there any competitors with distinct formulations of Rifaximin?
Currently, no. Most competitors focus on generic versions, lowering prices and expanding access.

5. Which emerging markets present the highest growth opportunities?
China and India, driven by increasing incidence of gastrointestinal conditions and improving healthcare infrastructure, present significant opportunities.

---

References

1. MarketsandMarkets. (2022). Rifaximin Market, Research Report.
2. U.S. Food and Drug Administration. (2019). Rifaximin Approvals and Labels.
3. IQVIA. (2022). Pharmaceuticals Sales Data.
4. Novo Nordisk. (2022). Xifaxan Annual Report.
5. Sandoz. (2023). Generic Drug Portfolio Announcements.